2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting

Christina H. Ruhlmann*, Karin Jordan, Franziska Jahn, Ernesto Maranzano, Alex Molassiotis, Kristopher Dennis

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

33 Downloads (Pure)

Abstract

Purpose: Radiotherapy and chemoradiotherapy-induced nausea and vomiting (RINV and C-RINV) are common and distressing, and there is a need for guidance for clinicians to provide up to date optimal antiemetic prophylaxis and treatment. Through a comprehensive review of the literature concerning RINV and C-RINV, this manuscript aims to update the evidence for antiemetic prophylaxis and rescue therapy and provide a new edition of recommendations for the MASCC/ESMO antiemetic guidelines for RINV and C-RINV. Methods: A systematic review of the literature including data published from May 1, 2015, to January 31, 2023, was performed. All authors assessed the literature. Results: The searches yielded 343 references; 37 met criteria for full article review, and 20 were ultimately retained. Only one randomized study in chemoradiation had the impact to provide new recommendations for the antiemetic guideline. Based on expert consensus, it was decided to change the recommendation for the “low emetic risk” category from “prophylaxis or rescue” to “rescue” only, while the drugs of choice remain unchanged. Conclusion: As for the previous guideline, the serotonin receptor antagonists are still the cornerstone in antiemetic prophylaxis of nausea and vomiting induced by high and moderate emetic risk radiotherapy. The guideline update provides new recommendation for the management of C-RINV for radiotherapy and concomitant weekly cisplatin. To avoid overtreatment, antiemetic prophylaxis is no longer recommended for the “low emetic risk” category.

Original languageEnglish
Article number26
JournalSupportive Care in Cancer
Volume32
Issue number1
Number of pages9
ISSN0941-4355
DOIs
Publication statusPublished - Jan 2024

Keywords

  • Antiemetic
  • Concomitant chemotherapy
  • Guideline
  • Nausea
  • Radiotherapy
  • Vomiting

Fingerprint

Dive into the research topics of '2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting'. Together they form a unique fingerprint.

Cite this